Investment Thesis
Matinas BioPharma faces critical operational and liquidity distress with revenue collapsing 65.6% YoY, operating cash burn of $1.6M against only $2.4M cash reserves, and negative net margins of -175.3%. The company has less than two quarters of cash runway at current burn rates, creating imminent going concern risk without significant capital infusion or operational turnaround.
Strengths
- Zero long-term debt eliminates leverage bankruptcy risk
- Current ratio of 1.32x provides adequate near-term liquidity coverage
- Net loss improved 5.6% YoY showing marginal operational progress
Risks
- Revenue collapse of 65.6% YoY indicates fundamental market or product failure
- Operating cash burn of $1.6M against $2.4M cash = <2 quarters runway to insolvency
- Deeply unprofitable operations with -175.3% net margin and no viable path to profitability
- Going concern risk requires immediate capital raise or company failure
- Minimal $5.9M asset base provides no operational cushion or collateral value
Key Metrics to Watch
- Cash balance and runway - primary survival metric
- Quarterly revenue trends - must stabilize to avoid bankruptcy
- Operating cash flow and burn rate - determines capital needs
- Capital raise announcements - only realistic path to avoid insolvency
Financial Metrics
Revenue
1.1M
Net Income
-1.9M
EPS (Diluted)
$-0.30
Free Cash Flow
-1.8M
Total Assets
5.9M
Cash
2.4M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-176.6%
Net Margin
-175.3%
ROE
-63.6%
ROA
-32.7%
FCF Margin
-166.0%
Balance Sheet & Liquidity
Current Ratio
1.32x
Quick Ratio
1.32x
Debt/Equity
0.00x
Debt/Assets
48.6%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-23T08:49:42.704134 |
Data as of: 2026-03-31 |
Powered by Claude AI